Peking University registers finerenone-semaglutide trial for obesity kidney disease
A new China-based study will test whether adding finerenone to semaglutide further lowers albuminuria in non-diabetic obese patients with chronic kidney disease.
A single new trial record was posted for the week, sponsored by Peking University People's Hospital.
- "Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria" (NCT07849348) is listed as not yet recruiting, with an estimated start of 2026-09. The trial will randomize about 266 participants 1:1, with a 24-week treatment period followed by a 4-week off-treatment follow-up.1 Participants will receive semaglutide plus finerenone or semaglutide plus matching finerenone placebo,1 and the primary objective is to compare change from baseline in UACR at Week 24.1 Bayer Healthcare Co., Ltd. is named among the study's collaborators.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.